Under construction – not a live service
Sign in
Taking people in RussiaNo phase

Cooling the Heart Artery to Limit Damage During Heart Attack Treatment

Tests cooling a blocked heart artery during treatment in adults having a heart attack.

Plain-language title generated from the registry record
Registry title: Intracoronary Hypothermia as a Prevention of Reperfusion Injury in Myocardial Infarction.

Key facts

Where
Tomsk, RussiaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Source: NCT06567249, who can take part

Where in Russia

  • Cardiology Research Institute, Tomsk National Research Medical CenterTomsk, RussiaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Tomsk National Research Medical Center of the Russian Academy of Sciences
Trial code
NCT06567249
Record updated
16 December 2025
Original description
Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary hypothermia, which showed to be safe on a handful of patients in small series. In the animal studies, intracoronary hypothermia demonstrated a protective effect in terms of reducing infarct area. But clinical studies failed to reproduce the protective effects of intracoronary hypothermia. Thus, our study, using a modified hypothermia protocol, will test the hypothermia hypothesis.Read full original descriptionShow less

Selective Intracoronary Hypothermia as a Prevention of Reperfusion Injury in ST-elevation Myocardial Infarction.

Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary hypothermia, which showed to be safe on a handful of patients in small series. In the animal studies, intracoronary hypothermia demonstrated a protective effect in terms of reducing infarct area. But clinical studies failed to reproduce the protective effects of intracoronary hypothermia. Thus, our study, using a modified hypothermia protocol, will test the hypothermia hypothesis.

Inclusion: Acute ST-elevation myocardial infarction; Time from onset of symptoms less than 12 hours; Given informed consent.

Exclusion: Active chemo/radiation therapy; Sick sinus syndrome requiring implantable pacemaker; Active inflammatory condition; Contraindication to MRI; Cardiogenic shock; Conduction disturbance: Atrioventricular block: 2nd and 3rd degree. SA block; Pulmonary edema.

ClinicalTrials.gov NCT06567249